Investigating genetic factors in heritable kidney cancer syndromes
Official title: Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes
Run by RenJi Hospital · NCT05534854 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is trying to learn more about the genetic causes of kidney cancer that runs in families to help improve care for those affected.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | RenJi Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT05534854 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals and their family members with a suspected or established diagnosis of heritable kidney cancer syndromes.
✕Probably not a fit
Patients without a genetic basis for their kidney cancer or those not related to affected individuals may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the frequency, clinical characteristics, and genetic underpinnings of heritable kidney cancer syndromes. Families with known or suspected genetic links to kidney cancer will be enrolled, and affected individuals will undergo clinical assessments and genetic analyses. The study seeks to define the natural history of these syndromes, establish genotype/phenotype correlations, and improve management strategies for patients and their families. Genetic testing will be utilized to understand the impact of mutations on disease manifestations.
Why it matters
Potential benefit: If successful, this study could lead to improved screening, prevention, and treatment strategies for individuals with heritable kidney cancer syndromes.
How similar studies have gone: Other studies have shown success in understanding genetic factors in cancer syndromes, making this approach promising but still requiring further exploration.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants must be greater than or equal to 2 years of age. All patients and guardians (for children younger than 18 years of age) must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed. Patients under the age of 18 but who are age 13 or older will be asked to sign an assent document prior to participation. * Individuals and biologic family members with a suspected or an established diagnosis of a heritable kidney cancer syndrome in which the disease gene is known, including von Hippel-Lindau (VHL) and hereditary papillary renal carcinoma (HPRC). * Individuals and biologic family members with a suspected or an established diagnosis of a heritable kidney cancer syndrome in which the disease gene is not yet known, specifically hereditary forms of Type II papillary renal cancer, clear cell renal carcinoma, renal oncocytoma, chromophobe renal carcinoma or Birt Hogg Dube. * Individuals and biologic family members who have heritable kidney cancer syndromes of suspected, but not proven genetic etiology, including families with more than one individual affected by the same or related cancers. * Subject Enrollment Categories (to include both affected and unaffected biologic relatives). Exclusion Criteria: * Pregnant women are excluded from enrollment onto this study because there is no direct benefit for participating in the study.
Where it's running
-
Ethics Committee of Shanghai Renji Hospital
Shanghai, Shanghai, China Recruiting
Study contacts
- Study coordinator: Yunze Xu, Ph.D.
- Email: rjxuyunze@163.com
- Phone: +8618801967501
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding how kidney tumors use nutrients for growth
This study tests how kidney tumors use certain nutrients to grow by giving participants a special nutrient infusion during surgery and checking their blood and tissue samples.
-
Investigating the genetic causes of hereditary kidney cancer
This study is trying to find out the genetic causes of hereditary kidney cancer to help people with this condition and their families understand their risks and health better.
-
Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home
This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.
-
Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer
This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.
-
Combining sasanlimab, palbociclib, and axitinib for metastatic kidney cancer
This test tries a combination of sasanlimab, palbociclib, and axitinib in people with advanced or metastatic clear cell or translocation renal cell carcinoma to see if it works and is safe.
-
Evaluating a new CAR T-cell therapy for solid tumors expressing EGFR
This study is testing a new CAR T-cell therapy to see if it can safely help adults with certain solid tumors, like colorectal and lung cancer, that have specific markers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.